Our candidates also included several genes typically considered TSGs, including CDKN1A (bladder carcinoma, 9.2% in TCGA), KMT2A (kidney carcinoma, 0.6%), MGA (ovarian carcinoma, 1.5%), PTEN (high-grade glioma, 14.2%), RB1 (lung adenocarcinoma, 5.0%), SMAD4 (ovarian carcinoma, 0.5%). This evidence concerns the gene SMAD4 and renal carcinoma.